Fecal Microbiota Transplantation Using RBX2660 for the Prevention of Recurrent Urinary Tract Infections Due to Multidrug Resistant Organisms

Trial Profile

Fecal Microbiota Transplantation Using RBX2660 for the Prevention of Recurrent Urinary Tract Infections Due to Multidrug Resistant Organisms

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs RBX 2660 (Primary)
  • Indications Urinary tract infections
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Dec 2017 Planned initiation date changed from 15 Dec 2017 to 2 Dec 2017.
    • 13 Jan 2016 New trial record
    • 11 Jan 2016 According to a Rebiotix media release, first patient has been treated in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top